-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Injury -X- _ O
to -X- _ O
the -X- _ O
kidney -X- _ O
epithelial -X- _ O
barrier -X- _ O
is -X- _ O
a -X- _ O
characteristic -X- _ O
feature -X- _ O
of -X- _ O
acute -X- _ O
kidney -X- _ O
injury -X- _ O
( -X- _ O
AKI -X- _ O
) -X- _ O
. -X- _ O
Serum -X- _ O
surfactant -X- _ O
protein-D -X- _ O
( -X- _ O
SP-D -X- _ O
) -X- _ O
, -X- _ O
a -X- _ O
known -X- _ O
biomarker -X- _ O
of -X- _ O
damaged -X- _ O
alveolar -X- _ O
epithelium -X- _ O
, -X- _ O
is -X- _ O
also -X- _ O
secreted -X- _ O
by -X- _ O
renal -X- _ O
tubular -X- _ O
epithelial -X- _ O
cells. -X- _ O
Therefore -X- _ O
, -X- _ O
the -X- _ O
aim -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
was -X- _ O
to -X- _ O
examine -X- _ O
the -X- _ O
possible -X- _ O
association -X- _ O
of -X- _ O
SP-D -X- _ B-Patient
with -X- _ I-Patient
AKI -X- _ I-Patient
susceptibility -X- _ O
and -X- _ O
prognosis. -X- _ O
METHODS -X- _ O
: -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
159 -X- _ B-Patient
AKI -X- _ I-Patient
patients -X- _ I-Patient
and -X- _ O
120 -X- _ B-Comparison
healthy -X- _ I-Comparison
individuals -X- _ I-Comparison
were -X- _ O
included. -X- _ O
SP-D -X- _ O
polymorphisms -X- _ O
Thr11Met -X- _ O
and -X- _ O
Thr160Ala -X- _ O
, -X- _ O
AKI -X- _ O
patient -X- _ O
serum -X- _ O
SP-D -X- _ O
levels -X- _ O
at -X- _ O
days -X- _ O
1 -X- _ O
, -X- _ O
3 -X- _ O
and -X- _ O
7 -X- _ O
and -X- _ O
urine -X- _ O
KIM-1 -X- _ O
levels -X- _ O
in -X- _ O
both -X- _ O
AKI -X- _ O
patients -X- _ O
and -X- _ O
controls -X- _ O
were -X- _ O
examined. -X- _ O
The -X- _ O
obtained -X- _ O
results -X- _ O
were -X- _ O
correlated -X- _ O
with -X- _ O
the -X- _ O
AKI -X- _ O
stage -X- _ O
, -X- _ O
duration -X- _ O
of -X- _ O
renal -X- _ O
replacement -X- _ O
therapy -X- _ O
( -X- _ O
RRT -X- _ O
) -X- _ O
and -X- _ O
prognosis. -X- _ O
RESULTS -X- _ O
: -X- _ O
Serum -X- _ B-Outcome
SP-D -X- _ I-Outcome
level -X- _ I-Outcome
in -X- _ I-Outcome
AKI -X- _ I-Outcome
patients -X- _ I-Outcome
was -X- _ I-Outcome
higher -X- _ I-Outcome
than -X- _ I-Outcome
controls -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.01 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
SP-D -X- _ I-Outcome
11Thr -X- _ I-Outcome
/ -X- _ I-Outcome
Thr -X- _ I-Outcome
genotype -X- _ I-Outcome
was -X- _ I-Outcome
more -X- _ I-Outcome
frequent -X- _ I-Outcome
in -X- _ I-Outcome
AKI -X- _ I-Outcome
patients -X- _ I-Outcome
than -X- _ I-Outcome
in -X- _ I-Outcome
controls -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.01 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
AKI -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
SP-D -X- _ I-Outcome
11Thr -X- _ I-Outcome
/ -X- _ I-Outcome
Thr -X- _ I-Outcome
genotype -X- _ I-Outcome
had -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
serum -X- _ I-Outcome
SP-D -X- _ I-Outcome
levels -X- _ I-Outcome
( -X- _ I-Outcome
p -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
) -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
other -X- _ I-Outcome
genotypes. -X- _ I-Outcome
Serum -X- _ I-Outcome
SP-D -X- _ I-Outcome
levels -X- _ I-Outcome
corrected -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
progression -X- _ I-Outcome
of -X- _ I-Outcome
AKI -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
peak -X- _ I-Outcome
at -X- _ I-Outcome
day -X- _ I-Outcome
3. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
SP- -X- _ I-Outcome
D -X- _ I-Outcome
11Thr -X- _ I-Outcome
/ -X- _ I-Outcome
Thr -X- _ I-Outcome
genotype -X- _ I-Outcome
frequency -X- _ I-Outcome
and -X- _ I-Outcome
baseline -X- _ I-Outcome
serum -X- _ I-Outcome
SP-D -X- _ I-Outcome
level -X- _ I-Outcome
were -X- _ I-Outcome
higher -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
who -X- _ I-Outcome
subsequently -X- _ I-Outcome
died. -X- _ I-Outcome
Baseline -X- _ I-Outcome
serum -X- _ I-Outcome
SP-D -X- _ I-Outcome
levels -X- _ I-Outcome
positively -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
urine -X- _ I-Outcome
KIM-1 -X- _ I-Outcome
levels -X- _ I-Outcome
, -X- _ I-Outcome
AKI -X- _ I-Outcome
stage -X- _ I-Outcome
and -X- _ I-Outcome
RRT -X- _ I-Outcome
duration. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
In -X- _ O
our -X- _ O
study -X- _ O
, -X- _ O
elevated -X- _ B-Outcome
serum -X- _ I-Outcome
SP-D -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
worse -X- _ I-Outcome
AKI -X- _ I-Outcome
clinical -X- _ I-Outcome
outcomes -X- _ I-Outcome
and -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
SP-D -X- _ I-Outcome
11Thr -X- _ I-Outcome
/ -X- _ I-Outcome
Thr -X- _ I-Outcome
genotype -X- _ I-Outcome
were -X- _ I-Outcome
more -X- _ I-Outcome
susceptible -X- _ I-Outcome
to -X- _ I-Outcome
AKI. -X- _ I-Outcome
Collectively -X- _ O
, -X- _ O
these -X- _ O
findings -X- _ O
suggest -X- _ O
that -X- _ O
SP-D -X- _ B-Outcome
may -X- _ I-Outcome
be -X- _ I-Outcome
useful -X- _ I-Outcome
as -X- _ I-Outcome
a -X- _ I-Outcome
biomarker -X- _ I-Outcome
of -X- _ I-Outcome
AKI -X- _ I-Outcome
susceptibility -X- _ I-Outcome
and -X- _ I-Outcome
prognosis -X- _ I-Outcome
. -X- _ O

